Related Experiment Video
Updated: Mar 1, 2026
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
Functional Optical Imaging of Primary Human Tumor Organoids: Development of a Personalized Drug Screen
Alex J Walsh1, Rebecca S Cook1,2, Melissa C Skala3,4
1Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee.
Abstract:
Primary tumor organoids are a robust model of individual human cancers and present a unique platform for patient-specific drug testing. Optical imaging is uniquely suited to assess organoid function and behavior because of its subcellular resolution, penetration depth through the entire organoid, and functional endpoints. Specifically, optical metabolic imaging (OMI) is highly sensitive to drug response in organoids, and OMI in tumor organoids correlates with primary tumor drug response. Therefore, an OMI organoid drug screen could enable accurate testing of drug response for individualized cancer treatment. The objective of this perspective is to introduce OMI and tumor organoids to a general audience in order to foster the adoption of these techniques in diverse clinical and laboratory settings.
Insights
Optical metabolic imaging (OMI) in tumor organoids accurately predicts patient drug response. This approach offers a powerful tool for personalized cancer treatment strategies, enhancing drug screening and clinical applications.
Area of Science:
- Oncology
- Biomedical Imaging
- Cancer Research
Background:
- Primary tumor organoids serve as advanced models for individual human cancers.
- Organoids offer a unique platform for patient-specific drug testing and personalized medicine.
- Optical imaging provides subcellular resolution and deep penetration for assessing organoid function.
Purpose of the Study:
- To introduce optical metabolic imaging (OMI) and tumor organoids to a broad audience.
- To promote the adoption of OMI and organoid technology in clinical and research settings.
- To highlight the potential of OMI organoid drug screening for individualized cancer therapy.
Main Methods:
- Utilizing primary tumor organoids as a model system for cancer drug testing.
- Employing optical metabolic imaging (OMI) to assess organoid function and drug response.
- Correlating OMI findings in organoids with primary tumor drug response data.
Main Results:
- Optical metabolic imaging (OMI) demonstrates high sensitivity to drug responses in tumor organoids.
- OMI in tumor organoids shows a strong correlation with actual primary tumor drug response.
- This correlation suggests OMI organoid screens can predict therapeutic efficacy.
Conclusions:
- OMI organoid drug screening is a viable method for predicting patient-specific cancer treatment outcomes.
- The integration of OMI and tumor organoids can significantly advance personalized oncology.
- Widespread adoption of these technologies promises to improve individualized cancer care.
